Please enable JavaScript to continue using this application.

Compare $RARE vs $TSHA | Chartloom

Compare

$RARE vs $TSHA

Ultragenyx Pharmaceutical Inc · Taysha Gene Therapies Inc

RARE

Ultragenyx Pharmaceutical Inc

TSHA

Taysha Gene Therapies Inc

Compare $RARE vs $TSHA

Comparing Ultragenyx Pharmaceutical Inc and Taysha Gene Therapies Inc

RAREUltragenyx Pharmaceutical Inc

TSHATaysha Gene Therapies Inc

RAREUltragenyx Pharmaceutical Inc

Market cap

$1.52B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

1.74x

Rev growth (TTM)

17.5%

YTD performance

-34.4%

52W performance

-49.8%

FCF yield

-32.4%

TSHATaysha Gene Therapies Inc

Market cap

$1.44B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

664.56x

Rev growth (TTM)

-32.3%

YTD performance

-14.5%

52W performance

-11.3%

FCF yield

-9.2%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

RARE

TSHA

Detailed metrics comparison

RARE

Ultragenyx Pharmaceutical Inc

TSHA

Taysha Gene Therapies Inc

Market Cap

RARE$1.52B

TSHA$1.44B

Enterprise Value

RARE$2.54B

TSHA$1.03B

Price

RARE$15.48

TSHA$4.49

P/E Ratio

RAREN/A

TSHAN/A

P/S Ratio

RARE2.13x

TSHA261.77x

EV/Sales

RARE3.54x

TSHA187.75x

EV/EBITDA

RARE0.00x

TSHA0.00x

P/B Ratio

RARE163.83x

TSHA3.90x

P/FCF Ratio

RAREN/A

TSHAN/A

EV/FCF

RARE-5.14x

TSHA-7.77x

PEG Ratio

RAREN/A

TSHAN/A

Forward P/E (NTM)

RAREN/A

TSHAN/A

Forward P/S (NTM)

RARE1.74x

TSHA664.56x

Revenue (TTM)

RARE$717M

TSHA$5M

Revenue Growth (YoY)

RARE17.5%

TSHA-32.3%

Forward Rev Growth

RARE27.7%

TSHA1272.3%

Gross Margin (TTM)

RARE83.1%

TSHA0.0%

Operating Margin (TTM)

RARE0.0%

TSHA0.0%

EBITDA Margin (TTM)

RARE-69.0%

TSHA-2833.6%

Net Margin (TTM)

RARE-81.7%

TSHA-2728.0%

FCF Margin (TTM)

RARE-68.9%

TSHA-2417.0%

Net Income (TTM)

RARE$-586M

TSHA$-150M

FCF (TTM)

RARE$-494M

TSHA$-133M

EPS (TTM)

RARE-$5.75

TSHA-$0.41

ROE (TTM)

RARE-41417.0%

TSHA-5619.0%

ROA (TTM)

RARE-4437.0%

TSHA-4184.0%

ROIC (TTM)

RARE-5861.0%

TSHA-4729.0%

Cash

RARE$125M

TSHA$455M

Debt

RARE$1.14B

TSHA$49M

Net Cash/Debt

RARE$-1.02B

TSHA$406M

Current Ratio (TTM)

RARE1.73x

TSHA17.76x

Quick Ratio (TTM)

RARE1.43x

TSHA17.57x

Debt/Equity (TTM)

RARE90.54x

TSHA0.13x

Debt/Assets (TTM)

RARE0.0%

TSHA0.0%

Interest Coverage (TTM)

RAREN/A

TSHAN/A

Net Debt/EBITDA (TTM)

RARE0.00x

TSHA0.00x

Beta

RARE0.35

TSHA1.37

52W Performance

RARE-49.8%

TSHA-11.3%

YTD Performance

RARE-34.4%

TSHA-14.5%

% from 52W High

RARE-61.2%

TSHA-38.5%

% from 52W Low

RARE21.6%

TSHA21.6%

Asset Turnover (TTM)

RARE0.54x

TSHA0.04x

FCF Yield (TTM)

RARE-32.4%

TSHA-9.2%

Earnings Yield (TTM)

RARE-38.4%

TSHA-10.4%

Dividend Yield (TTM)

RAREN/A

TSHAN/A

Rule of 40

RARE-51.4

TSHA-2,449.3

EV/GP/RG

RARE0.17

TSHAN/A

Ticker research

View RARE research View TSHA research

Metric	RARE Ultragenyx Pharmaceutical Inc	TSHA Taysha Gene Therapies Inc
Market & Valuation
Market Cap	$1.52B	$1.44B
Enterprise Value	$2.54B	$1.03B
Price	$15.48	$4.49
P/E Ratio	N/A	N/A
P/S Ratio	2.13x	261.77x
EV/Sales	3.54x	187.75x
EV/EBITDA	0.00x	0.00x
P/B Ratio	163.83x	3.90x
P/FCF Ratio	N/A	N/A
EV/FCF	-5.14x	-7.77x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	1.74x	664.56x
Revenue & Growth
Revenue (TTM)	$717M	$5M
Revenue Growth (YoY)	17.5%	-32.3%
Forward Rev Growth	27.7%	1272.3%
Profitability
Gross Margin (TTM)	83.1%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-69.0%	-2833.6%
Net Margin (TTM)	-81.7%	-2728.0%
FCF Margin (TTM)	-68.9%	-2417.0%
Net Income (TTM)	$-586M	$-150M
FCF (TTM)	$-494M	$-133M
EPS (TTM)	-$5.75	-$0.41
ROE (TTM)	-41417.0%	-5619.0%
ROA (TTM)	-4437.0%	-4184.0%
ROIC (TTM)	-5861.0%	-4729.0%
Financial Health
Cash	$125M	$455M
Debt	$1.14B	$49M
Net Cash/Debt	$-1.02B	$406M
Current Ratio (TTM)	1.73x	17.76x
Quick Ratio (TTM)	1.43x	17.57x
Debt/Equity (TTM)	90.54x	0.13x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.35	1.37
52W Performance	-49.8%	-11.3%
YTD Performance	-34.4%	-14.5%
% from 52W High	-61.2%	-38.5%
% from 52W Low	21.6%	21.6%
Efficiency & Yields
Asset Turnover (TTM)	0.54x	0.04x
FCF Yield (TTM)	-32.4%	-9.2%
Earnings Yield (TTM)	-38.4%	-10.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-51.4	-2,449.3
EV/GP/RG	0.17	N/A
Ticker research	View RARE research	View TSHA research

Valuation

P/S Ratio

RARE

2.13x

TSHA

261.77x

EV/FCF

TSHA

-7.77x

RARE

-5.14x

Growth & revenue

Revenue Growth TTM

RARE

17.5%

TSHA

-32.3%

Forward Revenue Growth

TSHA

1272.3%

RARE

27.7%

Profitability & performance

Gross Margin

RARE

83.1%

TSHA

0.0%

ROE

TSHA

-5619.0%

RARE

-41417.0%

FCF Yield %

TSHA

-9.2%

RARE

-32.4%

52-Week Performance

TSHA

-11.3%

RARE

-49.8%

Detailed metrics comparison

RARE

Ultragenyx Pharmaceutical Inc

TSHA

Taysha Gene Therapies Inc

Market Cap

RARE$1.52B

TSHA$1.44B

Enterprise Value

RARE$2.54B

TSHA$1.03B

Price

RARE$15.48

TSHA$4.49

P/E Ratio

RAREN/A

TSHAN/A

P/S Ratio

RARE2.13x

TSHA261.77x

EV/Sales

RARE3.54x

TSHA187.75x

EV/EBITDA

RARE0.00x

TSHA0.00x

P/B Ratio

RARE163.83x

TSHA3.90x

P/FCF Ratio

RAREN/A

TSHAN/A

EV/FCF

RARE-5.14x

TSHA-7.77x

PEG Ratio

RAREN/A

TSHAN/A

Forward P/E (NTM)

RAREN/A

TSHAN/A

Forward P/S (NTM)

RARE1.74x

TSHA664.56x

Revenue (TTM)

RARE$717M

TSHA$5M

Revenue Growth (YoY)

RARE17.5%

TSHA-32.3%

Forward Rev Growth

RARE27.7%

TSHA1272.3%

Gross Margin (TTM)

RARE83.1%

TSHA0.0%

Operating Margin (TTM)

RARE0.0%

TSHA0.0%

EBITDA Margin (TTM)

RARE-69.0%

TSHA-2833.6%

Net Margin (TTM)

RARE-81.7%

TSHA-2728.0%

FCF Margin (TTM)

RARE-68.9%

TSHA-2417.0%

Net Income (TTM)

RARE$-586M

TSHA$-150M

FCF (TTM)

RARE$-494M

TSHA$-133M

EPS (TTM)

RARE-$5.75

TSHA-$0.41

ROE (TTM)

RARE-41417.0%

TSHA-5619.0%

ROA (TTM)

RARE-4437.0%

TSHA-4184.0%

ROIC (TTM)

RARE-5861.0%

TSHA-4729.0%

Cash

RARE$125M

TSHA$455M

Debt

RARE$1.14B

TSHA$49M

Net Cash/Debt

RARE$-1.02B

TSHA$406M

Current Ratio (TTM)

RARE1.73x

TSHA17.76x

Quick Ratio (TTM)

RARE1.43x

TSHA17.57x

Debt/Equity (TTM)

RARE90.54x

TSHA0.13x

Debt/Assets (TTM)

RARE0.0%

TSHA0.0%

Interest Coverage (TTM)

RAREN/A

TSHAN/A

Net Debt/EBITDA (TTM)

RARE0.00x

TSHA0.00x

Beta

RARE0.35

TSHA1.37

52W Performance

RARE-49.8%

TSHA-11.3%

YTD Performance

RARE-34.4%

TSHA-14.5%

% from 52W High

RARE-61.2%

TSHA-38.5%

% from 52W Low

RARE21.6%

TSHA21.6%

Asset Turnover (TTM)

RARE0.54x

TSHA0.04x

FCF Yield (TTM)

RARE-32.4%

TSHA-9.2%

Earnings Yield (TTM)

RARE-38.4%

TSHA-10.4%

Dividend Yield (TTM)

RAREN/A

TSHAN/A

Rule of 40

RARE-51.4

TSHA-2,449.3

EV/GP/RG

RARE0.17

TSHAN/A

Ticker research

View RARE research View TSHA research

Metric	RARE Ultragenyx Pharmaceutical Inc	TSHA Taysha Gene Therapies Inc
Market & Valuation
Market Cap	$1.52B	$1.44B
Enterprise Value	$2.54B	$1.03B
Price	$15.48	$4.49
P/E Ratio	N/A	N/A
P/S Ratio	2.13x	261.77x
EV/Sales	3.54x	187.75x
EV/EBITDA	0.00x	0.00x
P/B Ratio	163.83x	3.90x
P/FCF Ratio	N/A	N/A
EV/FCF	-5.14x	-7.77x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	1.74x	664.56x
Revenue & Growth
Revenue (TTM)	$717M	$5M
Revenue Growth (YoY)	17.5%	-32.3%
Forward Rev Growth	27.7%	1272.3%
Profitability
Gross Margin (TTM)	83.1%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-69.0%	-2833.6%
Net Margin (TTM)	-81.7%	-2728.0%
FCF Margin (TTM)	-68.9%	-2417.0%
Net Income (TTM)	$-586M	$-150M
FCF (TTM)	$-494M	$-133M
EPS (TTM)	-$5.75	-$0.41
ROE (TTM)	-41417.0%	-5619.0%
ROA (TTM)	-4437.0%	-4184.0%
ROIC (TTM)	-5861.0%	-4729.0%
Financial Health
Cash	$125M	$455M
Debt	$1.14B	$49M
Net Cash/Debt	$-1.02B	$406M
Current Ratio (TTM)	1.73x	17.76x
Quick Ratio (TTM)	1.43x	17.57x
Debt/Equity (TTM)	90.54x	0.13x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.35	1.37
52W Performance	-49.8%	-11.3%
YTD Performance	-34.4%	-14.5%
% from 52W High	-61.2%	-38.5%
% from 52W Low	21.6%	21.6%
Efficiency & Yields
Asset Turnover (TTM)	0.54x	0.04x
FCF Yield (TTM)	-32.4%	-9.2%
Earnings Yield (TTM)	-38.4%	-10.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-51.4	-2,449.3
EV/GP/RG	0.17	N/A
Ticker research	View RARE research	View TSHA research